Dr Reddy’s

Dr. Reddy’s Laboratories has entered into a landmark licensing agreement with Australian biotechnology firm Immutep to develop and commercialize a promising cancer immunotherapy candidate. The collaboration aims to accelerate clinical progress and expand global access to a next-generation treatment designed to enhance the body’s immune response against tumors. By combining Dr. Reddy’s manufacturing scale and commercialization expertise with Immutep’s scientific innovation, the partnership signals a major step in oncology research.

In a significant development within the pharmaceutical industry, Indian drugmakers Glenmark Pharmaceuticals and Dr. Reddy's Laboratories have initiated product recalls in the United States due to manufacturing issues, as reported by the U.S. Food and Drug Administration (USFDA). These actions underscore the ongoing challenges faced by global pharmaceutical companies in maintaining stringent quality control standards across diverse manufacturing facilities.

Pharmaceutical giants Dr. Reddy’s Laboratories and Zydus Lifesciences have initiated voluntary recalls of select drug batches in the United States following notifications from the US Food and Drug Administration (USFDA). The recalls pertain to concerns over quality control and compliance with manufacturing standards, underscoring the regulator’s commitment to patient safety. Affected products include widely used generic medications distributed through multiple channels.

Dr. Reddy’s Laboratories has unveiled Colozo, a new therapeutic option designed for individuals suffering from chronic constipation. The launch reflects the company’s ongoing focus on gastrointestinal health and patient-centric innovation. Colozo, formulated to improve bowel regularity and ease discomfort, is expected to address a significant unmet need in the gastrointestinal treatment market. Analysts anticipate that the product could strengthen Dr. Reddy’s presence in the specialty healthcare segment while providing a safe, effective alternative for patients.

Dr Reddy’s Laboratories reported that the U.S. Food and Drug Administration (FDA) conducted a Good Manufacturing Practice (GMP) inspection at its Middleburgh, New York API manufacturing site between May 12 and 16, 2025. The regulatory body issued a Form 483 citing two observations that require remedial action. Form 483 notifications signify potential compliance issues under the Food, Drug, and Cosmetic Act. Dr Reddy’s affirmed its commitment to resolving the observations within the designated timeframe.